TScan scrapped its heme TCR-T identity after running out of money mid-Phase 3; what survives is a preclinical in vivo solid tumor bet with runway to Q4 2027

TScan is a clinical-stage cell therapy company developing engineered T cell treatments for blood cancers and solid tumors, though its lead program treating acute myeloid leukemia is not yet approved and has been paused mid-trial due to funding constraints.

Built around TCR-engineered T cells for AML and MDS after stem cell transplant, TScan paused its Phase 3 trial mid-enrollment for lack of capital, cut 75% of its workforce, and lost its $530 million Amgen partnership. What remains is a preclinical in vivo TCR-T program targeting PRAME and MAGE-A4 in solid tumors, explicitly unproven with no human data. Runway extends only to Q4 2027, before any Phase 1 data could realistically mature, making survival to proof-of-concept dependent on external financing.